Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Hua-Dong Chen"'
Autor:
Ying Huang, Jieyi Ma, Cuiyun Yang, Paijia Wei, Minghui Yang, Hui Han, Hua Dong Chen, Tianfang Yue, Shu Xiao, Xuanyu Chen, Zuoqing Li, Yanlai Tang, Jiesi Luo, Shuibin Lin, Libin Huang
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-14 (2022)
Abstract Background Neuroblastoma (NBL) is the most common extra-cranial solid tumour in childhood, with prognosis ranging from spontaneous remission to high risk for rapid and fatal progression. Despite existing therapy approaches, the 5-year event-
Externí odkaz:
https://doaj.org/article/a9a8275a837b457d891440d2529e03f8
Autor:
Li‐Min Wang, Pingyuan Wang, Xiao‐Min Chen, Hui Yang, Shan‐Shan Song, Zilan Song, Li Jia, Hua‐Dong Chen, Xu‐Bin Bao, Ne Guo, Xia‐Juan Huan, Yong Xi, Yan‐Yan Shen, Xin‐Ying Yang, Yi Su, Yi‐Ming Sun, Ying‐Lei Gao, Yi Chen, Jian Ding, Jing‐Yu Lang, Ze‐Hong Miao, Ao Zhang, Jin‐Xue He
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 3, Pp n/a-n/a (2023)
Abstract Poly‐ADP‐ribose polymerase (PARP) inhibitors (PARPi) have shown great promise for treating BRCA‐deficient tumors. However, over 40% of BRCA‐deficient patients fail to respond to PARPi. Here, we report that thioparib, a next‐generat
Externí odkaz:
https://doaj.org/article/24325773452c46108ba801e5debd9f21
Autor:
Ning Zhang, Yu-Nan Tian, Li-Na Zhou, Meng-Zhu Li, Hua-Dong Chen, Shan-Shan Song, Xia-Juan Huan, Xu-Bin Bao, Ao Zhang, Ze-Hong Miao, Jin-Xue He
Publikováno v:
Cell Death and Disease, Vol 12, Iss 2, Pp 1-18 (2021)
Abstract Monotherapy with poly ADP-ribose polymerase (PARP) inhibitors results in a limited objective response rate (≤60% in most cases) in patients with homologous recombination repair (HRR)-deficient cancer, which suggests a high rate of resistan
Externí odkaz:
https://doaj.org/article/aa58f0bfd0a740678bf052d1f92375c9
Publikováno v:
Cancer Biology & Therapy
article-version (VoR) Version of Record
article-version (VoR) Version of Record
PARP1 and Chk1 inhibitors have been shown to be synergistic in different cancer models in relatively short time treatment modes. However, the consequences of long-term/repeated treatments with the combinations in cancer models remain unclear. In this
Autor:
Li‐Min Wang, Pingyuan Wang, Xiao‐Min Chen, Hui Yang, Shan‐Shan Song, Zilan Song, Li Jia, Hua‐Dong Chen, Xu‐Bin Bao, Ne Guo, Xia‐Juan Huan, Yong Xi, Yan‐Yan Shen, Xin‐Ying Yang, Yi Su, Yi‐Ming Sun, Ying‐Lei Gao, Yi Chen, Jian Ding, Jing‐Yu Lang, Ze‐Hong Miao, Ao Zhang, Jin‐Xue He
Publikováno v:
EMBO Molecular Medicine. 15
Autor:
Ze-Hong Miao, Hua-Dong Chen, Lin Chen, Bing Xiong, Jianping Hu, Chang-Qing Tian, Huan Xiajuan, Ying-Qing Wang, Jingkang Shen
Publikováno v:
Cell Death and Disease, Vol 10, Iss 8, Pp 1-13 (2019)
Cell Death & Disease
Cell Death & Disease
The bromodomain and extra terminal domain (BET) family members, including BRD2, BRD3, and BRD4, act as epigenetic readers to regulate gene expression. Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that participates in tumor immune escape primaril
Autor:
Chuan-Huizi Chen, Hua-Dong Chen, Shanshan Song, Jin-Xue He, Ze-Hong Miao, Huan Xiajuan, Ne Guo, Yu-Nan Tian, Yu-Ting Wang
Publikováno v:
International Journal of Cancer. 145:714-727
PARP1 inhibitors (PARPis) are used clinically during cancer therapy and are thought to exert their cytotoxicity through PARP1 polymerase inhibition and PARP1-DNA trapping. Here, we showed no significant correlation between PARP1-DNA trapping and cyto
Publikováno v:
Cancer gene therapy. 29(7)
N
Autor:
Chih-Hsin Tang, Hua-Dong Chen, Qian Wang, Guinv Hu, Lulu Jin, Yan Wang, Chao-Qun Wang, Jun-Kang Shao, Xiao-Fang Dong
Publikováno v:
Medicine
Although some studies have reported the expression and clinical significance of phosphorylated signal transducer and activator of transcription 3 (p-STAT3) in breast cancer tissues, it is still controversial whether p-STAT3 play a role in promoting o
Autor:
Hua-Dong Chen, Jin-Xue He, Xu-Bin Bao, Meng-Zhu Li, Huan Xiajuan, Ze-Hong Miao, Ning Zhang, Ao Zhang, Yu-Nan Tian, Li-Na Zhou, Shanshan Song
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 12, Iss 2, Pp 1-18 (2021)
Cell Death and Disease, Vol 12, Iss 2, Pp 1-18 (2021)
Monotherapy with poly ADP-ribose polymerase (PARP) inhibitors results in a limited objective response rate (≤60% in most cases) in patients with homologous recombination repair (HRR)-deficient cancer, which suggests a high rate of resistance in thi